Skip to main content
. 2015 Oct 16;7(1):946–960. doi: 10.18632/oncotarget.5834

Figure 1. Simvastatin inhibited the growth of ovarian cancer cells and HMGCR activity.

Figure 1

Hey and SKOV3 cells were cultured for 24 h and then treated with varying concentrations of simvastatin in 96 well plates for 72 h. Cell proliferation was assessed by MTT assay A. The effect of simvastatin on its target, HMGCR, was examined by Western blot analysis. Simvastatin treatment resulted in a dose-dependent decrease in expression of HMGCR protein in both cell lines B. HMGCR activity in ovarian cancer cells was measured via HMGCR Assay. Treatment with simvastatin for 24 h resulted in a dose-dependent decrease in HMGCR activity in both the Hey and SKOV3 cell lines C. Each experiment was performed three times. C in graphs refers to control. (*p < 0.05, **p < 0.01).